In this study, the patients will randomly receive either Promacta/Vidaza combination every 28 days for at least 6 cycles, or placebo plus Vidaza. The primary endpoint of the study is to compare the ...
Promacta ® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low platelet ...
Promacta (eltrombopag) can cause side effects ranging from mild issues like nausea and fatigue to more serious complications, such as cataracts. Promacta has boxed warnings about the potential for ...
Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with ...
The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...
First supportive care treatment approved for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy LONDON, Nov. 19, 2012 ...
PHILADELPHIA, Dec. 6 GlaxoSmithKline (NYSE: GSK)announced positive safety and efficacy results from RAISE (RAndomized placebo-controlled ITP Study with Eltrombopag), a Phase III study of ...
Novartis’ Promacta has been given Breakthrough Therapy Designation by the FDA for previously untreated patients with severe aplastic anaemia (SAA). The Swiss pharma giant has been uniquely successful ...
Promacta (eltrombopag) is a brand-name drug prescribed for certain blood conditions. Promacta has interactions with some supplements and drugs. Examples include some antacids and certain statins. An ...
GlaxoSmithKline (NYSE:GSK) now wants approval to use its low platelet drug Promacta to treat hepatitis C patients. The British pharmaceutical giant, which has its U.S. headquarters in Research ...
The US FDA has approved GlaxoSmithKline’s promacta for the additional use of treating hepatitis C patients with a low platelet count who are unable to undergo standard hepatitis C therapy. Promacta ...
The company is recalling the lots because of possible peanut flour contamination. Novartis announced on May 11, 2019 that it was recalling three lots of Promacta (eltrombopag) 12.5 mg for oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results